Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 168
- Registration Number
- NCT00096135
- Locations
- 🇺🇸
CancerCare of Maine at Eastern Maine Medical Center, Bangor, Maine, United States
🇺🇸Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)
- Conditions
- Carcinoma, Adrenal Cortical
- Interventions
- First Posted Date
- 2004-10-20
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- Collaborative Group for Adrenocortical Carcinoma Treatment
- Target Recruit Count
- 304
- Registration Number
- NCT00094497
- Locations
- 🇺🇸
National Cancer Institute - Center for Cancer Research, Bethesda, Maryland, United States
🇺🇸University of Michigan, Department of Internal Medicine, Ann Arbor, Michigan, United States
🇦🇺Royal Adelaide Hospital, Adelaide, Australia
Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: Bleomycin SulfateBiological: FilgrastimDrug: CyclophosphamideDrug: CytarabineDrug: CisplatinDrug: Doxorubicin Hydrochloride (DOX)Drug: FluorouracilDrug: Leucovorin calciumDrug: EtoposideDrug: PentamidineDrug: PrednisoneDrug: IfosfamideDrug: Trimethoprim-SulfamethoxazoleDrug: MethotrexateDrug: Vincristine SulfateDrug: MethylprednisoloneDrug: Zidovudine (AZT)Radiation: Radiation Therapy
- First Posted Date
- 2004-10-05
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT00002524
- Locations
- 🇺🇸
MD Anderson Cancer Center Orlando, Orlando, Florida, United States
🇺🇸University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
- Conditions
- Lymphoproliferative DisorderHIVHHV-8Malignancy
- Interventions
- First Posted Date
- 2004-09-22
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 75
- Registration Number
- NCT00092222
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2004-09-16
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Loyola University
- Registration Number
- NCT00004905
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Loyola University Medical Center, Maywood, Illinois, United States
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma
- Conditions
- Brain TumorsCentral Nervous System Tumors
- Interventions
- First Posted Date
- 2004-09-13
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 7
- Registration Number
- NCT00003625
- Locations
- 🇺🇸
Baptist Hospital of Miami, Miami, Florida, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Lucile Packard Children's Hospital at Stanford, Palo Alto, California, United States
Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Conditions
- Leukemia
- Interventions
- Biological: filgrastimDrug: cladribineDrug: cytarabineDrug: etoposideDrug: methotrexateDrug: mitoxantrone hydrochlorideDrug: therapeutic hydrocortisoneProcedure: allogeneic bone marrow transplantationProcedure: autologous bone marrow transplantationProcedure: peripheral blood stem cell transplantationRadiation: low-LET cobalt-60 gamma ray therapyRadiation: low-LET electron therapyRadiation: low-LET photon therapy
- First Posted Date
- 2004-09-02
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 115
- Registration Number
- NCT00002805
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-08-31
- Last Posted Date
- 2010-10-01
- Lead Sponsor
- Temple University
- Registration Number
- NCT00002509
- Locations
- 🇺🇸
Temple University Cancer Center, Philadelphia, Pennsylvania, United States
Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors
- Conditions
- Extragonadal Germ Cell TumorOvarian Cancer
- First Posted Date
- 2004-08-30
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00002489
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
- Conditions
- LeukemiaLymphoma
- First Posted Date
- 2004-08-30
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00002471
- Locations
- 🇺🇸
Kaplan Cancer Center, New York, New York, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.